多西他赛腹腔灌注联合卡培他滨治疗晚期胃癌疗效分析

Effective analysis of intraperitoneal perfusion of docetaxel combined with capecitabine in treating advanced gastric cancer

目的 观察腹腔灌注多西他赛联合卡培他滨（希罗达）治疗晚期胃癌疗效及安全性.方法 共入组经病理证实的晚期胃癌患者40例,治疗方案为多西他赛60 mg,腹腔灌注;希罗达2 000 mg/m2,口服,每天2次,第1～14天用药,之后休息1周,21 d为1个周期,至少用药2个周期后进行疗效评价.结果 化疗4个周期后,完全缓解1例（2.5%）,部分缓解24例（60.0%）,疾病稳定12例（30.0%）,疾病进展3例（7.5%）,客观有效率62.5%（25/40）,平均中位无进展生存期为6.5个月,平均中位生存期为15.3个月,主要不良反应为骨髓抑制、胃肠道反应及手足综合征.结论 腹腔灌注多西他赛联合希罗达治疗晚期胃癌疗效较好,毒性可耐受.

Objective To evaluate the efficacy and safety of intraperitoneal perfusion of docetaxel combined with capeeitabine （xeloda） in the treatment of advanced gastric cancer. Methods A total of 40 patients diagnosed with advanced gas- tric cancer by histological examination of biopsy specimens were recruited. Docetaxel was perfused into peritoneal cavity at a dose of 60 mg;Xeloda was taken orally at a dose of 2 000 mg/m2,twice a day,on days 1-14,1 week for rest,the cycles were repeated every 21 days, and the evaluation of efficacy and safety were performed on all patients after 2 cycles at least. Results After 4 cy- cles of chemotherapy, 1 case was of complete remission accounting for 2.5% ; 24 cases were of partial remission accounting for 60.0% ; 12 cases were of stable disease accounting for 30.0% and 3 cases were with progressive disease accounting for 7.5% ;the objective response rate was 62.5% ;the median progression-free survival was 6.5 months and the median survival was 15.3 months. The major adverse reactions were myelosuppressio, nausea, vomiting and hand-foot syndrome. Conclusion Intraperitoneal perfu- sion of docetaxel combined with xeloda for advanced gastric cancer is safe and effective. Drug-related adverse events are mild with well toleration.